SynthesisSaudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
A systematic review on the safety and effectiveness of yttrium-90 radioembolization for hepatocellular carcinoma with portal vein tumor thrombosis.
Synthesis in Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Efficient recovery of YTurkish journal of chemistry · 2025Article
- Yttrium-90 radioembolization treatment strategies for management of hepatocellular carcinoma.World journal of radiology · 2024Review
- Contemporary applications of Y90 for the treatment of hepatocellular carcinoma.Hepatology communications · 2023Article
- Long-term outcome analysis of Y90 radioembolization in hepatocellular carcinoma.Journal of gastrointestinal oncology · 2023Article
- New Regimen of Combining Hepatic Arterial Infusion Chemotherapy and Lipiodol Embolization in Treating Hepatocellular Carcinoma with Main Portal Vein Invasion.Journal of personalized medicine · 2022Article
- Treatments of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: Current Status and Controversy.Journal of clinical and translational hepatology · 2022Review
- Clinical Management of Liver Cancer in India and Other Developing Nations: A Focus on Radiation Based Strategies.Oncology and therapy · 2021Review
- Advances in locoregional therapy for hepatocellular carcinoma combined with immunotherapy and targeted therapy.Journal of interventional medicine · 2021Review
- Locoregional Therapy Approaches for Hepatocellular Carcinoma: Recent Advances and Management Strategies.Cancers · 2020Review
- Contralateral Liver Hypertrophy and Oncological Outcome Following Radioembolization withCancers · 2020Review
- Hepatocellular carcinoma and macrovascular tumor thrombosis: treatment outcomes and prognostic factors for survival.Japanese journal of radiology · 2019Article
- Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers.World journal of gastroenterology · 2019Review
- Radioembolization in the setting of liver transplantation: great expectations or hard times?Hepatobiliary surgery and nutrition · 2018Article
- New Evidence and Perspectives on the Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.Journal of clinical and translational hepatology · 2017Review
- Treatment of hepatocellular carcinoma with portal vein tumor thrombus: advances and challenges.Oncotarget · 2017Review
- 2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations.Journal of clinical and experimental hepatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimOver the past two decades, several advances have been made in the management of patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT). Yttrium-90 ( 90 Y) radioembolization has recently been made a treatment option for patients with HCC and PVTT. However, there is still a need to systematicly evaluate the outcomes of 90 Y radioembolization for HCC and PVTT. We aimed to assess the safety and effectiveness of 90 Y radioembolization for HCC and PVTT. We performed a systematic review of clinical trials, clinical studies, and abstracts from conferences that qualified for analysis. MATERIALS AND
methodsPubMed, EMBASE, Cochrane Database of Systematic Review, CINAHL, and the "gray" literature (Google Scholar) were searched for all reports (1991-2016) related to 90 Y radioembolization for HCC and PVTT.
resultsA total of 14 clinical studies and three abstracts from conferences including 722 patients qualified for the analysis. The median length of follow-up was 7.2 months; the median time to progression was 5.6 months, and median disease control rate was 74.3%. Radiological response data were reported in five studies, and the median reported value of patients with complete response, partial response, stable disease, and progressive disease were 3.2%, 16.5%, 31.3%, and 28%, respectively. The median survival was 9.7 months for all patients, including the median overall survival (OS) were 12.1, 6.1 months of Child-Pugh class A and B patients, and the median OS were 6.1, 13.4 months of main and branch PVTT patients, respectively. The common toxicities were fatigue, nausea/vomiting, abdominal pain, mostly not requiring medical intervention needed no medication intervention.
conclusions90 Y radioembolization is a safe and effective treatment for HCC and PVTT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.